MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer.

Authors
Publication date
23 May 2023
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Ezid

    redirect
    oaiark:/13030/qt64c0v86n
    Last time updated on 02/06/2023